Affluense AI AFFLUENSE

🔓 Unlock the full profile of Peter Wagner (Fluxus, Inc.), including verified contact details, financial insights, and professional associations.

See Peter Wagner Full Profile

Below are the ✅ Verified Contact Details to help you connect directly:

Email: pet*****@flu******.com

Mobile: 91297*****

Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)

Key Insights You Should Know About This Individual
  • Peter Wagner is the President, Chief Executive Officer, Co-Founder, and a member of the Board of Directors at Fluxus Inc., a company based in Sunnyvale, California, focused on innovative solutions in biotechnology.
  • Starting in 2016, Wagner has played a pivotal role in driving Fluxus Inc.'s mission to develop advanced technologies aimed at enhancing the understanding of biology and improving healthcare outcomes.
  • As the President and Founder of Coincident Biosciences LLC since 2015, Wagner contributed significantly to the development of bioscience technologies, which are crucial for advancing medical research.
  • Previously served as Co-Founder and a Board Member at S2 Genomics from 2016 until January 2023, contributing to groundbreaking advancements in genomic technologies.
  • Wagner was instrumental as President and Chief Executive Officer of Zyomyx, Inc., from 2004 until 2014, focusing on innovative solutions in protein research and diagnostics.
  • Before that, Wagner held the positions of Senior Vice President and Chief Technology Officer at Zyomyx, contributing to the establishment of the company’s technology foundations.
  • Wagner's academic background includes serving as an Alexander-von-Humboldt Fellow at Stanford University School of Medicine and postdoctoral research at the Swiss Federal Institute of Technology (ETH), providing a strong foundation in research and development in the field of biotechnology.
  • Under Wagner's leadership, Fluxus Inc. has experienced significant headcount growth, indicating a strong organizational development and an expanding workforce that reflects the company's success in the biotechnology sector.